Investigator to discuss assay built on VeraTag(TM) technology's ability to
predict response to Herceptin(R)
SOUTH SAN FRANCISCO, Calif., May 16 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that scientific collaborators will present results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2 and predict response to Herceptin(R) (trastuzumab) in patients with metastatic breast cancer at the upcoming 44th ASCO Annual Meeting taking place in Chicago, Illinois.
The oral presentation, entitled "Total HER2 and HER2 Homodimer Levels Predict Response to trastuzumab", which will take place on Monday, June 2, 2008 from 1:15PM - 2:45PM, will discuss the findings of a study that investigated the HERmark assay's ability to identify and discriminate among patients with metastatic breast cancer who experienced different degrees of response to trastuzumab. The results of the study, by Allan Lipton, M.D. and colleagues at the Experimental Oncology Research Lab at Penn State/Hershey Medical Center will be presented by Kim Leitzel, M.Sc., Senior Research Associate in Dr. Lipton's laboratory.
"Current testing methods for determination of the likelihood of benefit from Herceptin are not adequate," said Allan Lipton M.D., Professor of Medicine & Oncology at Hershey Medical Center/Penn State University. "HERmark represents a promising new technology that could provide enhanced information on which patient therapy decisions may be based."
"HERmark is the first diagnostic built upon our VeraTag technology,"
said Monogram CEO Bill Young. "We believe HERmark represents an advance in
the field by providing very reproducible quantitative measures of HER2
|SOURCE Monogram Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved